MaaT Pharma is focused on developing microbiome-related therapies and its lead candidate is MaaT013, a treatment for acute ...

The French company has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.

New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 ...

A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning ...

OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...

Objective Juvenile SLE (jSLE) is an autoimmune disease characterised by the presence of high levels of autoantibodies, ...

Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.

Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...

Getty ImagesWith around 5% of COVID-19 patients estimated to develop long COVID, it remains a global health issue.To help ...

This low-calorie, low-carb commercial diet plan offers fast weight loss overseen by a health care professional.

Acurx has now received positive written responses from the EMA (European Medicines Agency) under its Scientific Advice Procedure that the clinical, non-clinical and ...